|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2007-8-8
|
|
pubmed:abstractText |
It was recently reported that high expression of peroxisome proliferator-activated receptor gamma (PPARgamma) and low expression of cyclooxygenase-2 (COX-2) might be involved in the inhibition of ovarian tumor progression and confirmed that PPARgamma activation could suppress COX-2 expression via the nuclear factor-kappaB pathway in ovarian cancer cells.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase 2,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase 2 Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Dinoprostone,
http://linkedlifedata.com/resource/pubmed/chemical/Intramolecular Oxidoreductases,
http://linkedlifedata.com/resource/pubmed/chemical/PPAR gamma,
http://linkedlifedata.com/resource/pubmed/chemical/Thiazines,
http://linkedlifedata.com/resource/pubmed/chemical/Thiazoles,
http://linkedlifedata.com/resource/pubmed/chemical/Thiazolidinediones,
http://linkedlifedata.com/resource/pubmed/chemical/Vascular Endothelial Growth Factor A,
http://linkedlifedata.com/resource/pubmed/chemical/ciglitazone,
http://linkedlifedata.com/resource/pubmed/chemical/meloxicam,
http://linkedlifedata.com/resource/pubmed/chemical/prostaglandin-E synthase
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
110
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
791-800
|
|
pubmed:meshHeading |
pubmed-meshheading:17582802-Animals,
pubmed-meshheading:17582802-Apoptosis,
pubmed-meshheading:17582802-Ascites,
pubmed-meshheading:17582802-Blotting, Western,
pubmed-meshheading:17582802-Cell Line, Tumor,
pubmed-meshheading:17582802-Cell Proliferation,
pubmed-meshheading:17582802-Cyclooxygenase 2,
pubmed-meshheading:17582802-Cyclooxygenase 2 Inhibitors,
pubmed-meshheading:17582802-Dinoprostone,
pubmed-meshheading:17582802-Female,
pubmed-meshheading:17582802-Humans,
pubmed-meshheading:17582802-Immunohistochemistry,
pubmed-meshheading:17582802-Intramolecular Oxidoreductases,
pubmed-meshheading:17582802-Mice,
pubmed-meshheading:17582802-Mice, Inbred BALB C,
pubmed-meshheading:17582802-Mice, Nude,
pubmed-meshheading:17582802-Ovarian Neoplasms,
pubmed-meshheading:17582802-PPAR gamma,
pubmed-meshheading:17582802-Peritoneal Neoplasms,
pubmed-meshheading:17582802-Survival Analysis,
pubmed-meshheading:17582802-Thiazines,
pubmed-meshheading:17582802-Thiazoles,
pubmed-meshheading:17582802-Thiazolidinediones,
pubmed-meshheading:17582802-Vascular Endothelial Growth Factor A,
pubmed-meshheading:17582802-Xenograft Model Antitumor Assays
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, on the growth of human ovarian cancers.
|
|
pubmed:affiliation |
Department of Obstetrics and Gynecology, Hirosaki University School of Medicine, Hirosaki, Aomori, Japan.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
